Shilpa Medicare Limited (BOM:530549)

Market Cap	63.80B -6.6%
Revenue (ttm)	14.33B +14.8%
Net Income	1.50B +70.0%
EPS	10.33 +121.8%
Shares Out	195.58M
PE Ratio	31.58
Forward PE	20.18
Dividend	0.50 (0.15%)
Ex-Dividend Date	Sep 17, 2025

Volume	11,819
Average Volume	43,965
Open	333.30
Previous Close	331.60
Day's Range	322.00 - 333.30
52-Week Range	260.00 - 501.60
Beta	0.04
RSI	59.04
Earnings Date	Feb 6, 2026

About Shilpa Medicare

Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clo...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1987
• Employees: 998
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530549

Financial Performance

In fiscal year 2025, Shilpa Medicare's revenue was 12.88 billion, an increase of 11.69% compared to the previous year's 11.53 billion. Earnings were 782.93 million, an increase of 145.63%.